Globus Medical shares the details from its earnings call for the second quarter of 2026.

Oct 12, 2026, 6:29 AM ETResultsRead the original at Benzinga

Good for GMED

Globus Medical reported 6% sales growth, rising to 9% excluding Nevro, and profit per share rose 56%. Reported growth was lower, but gains across spine sales and a higher 2026 profit forecast support the company’s outlook.

GMED · Globus Medical

AI read · Good for GMED

The AI's read

Growth reached both U.S. and overseas spine sales, alongside a sharp rise in profit per share. The company also raised its 2026 profit-per-share forecast. Reported sales rose 6%, compared with 9% excluding Nevro, but gains across spine sales and the higher forecast support a stronger outlook.

Get alerts for GMED

Follow Globus Medical (GMED) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GMED

Free on the App Store and Google Play, or on the web.